Drug Profile
Seasonal influenza virus vaccine - Takeda
Alternative Names: Preflucel; Vero cell-derived trivalent seasonal influenza vaccine - TakedaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Baxter International
- Developer Baxalta; Takeda
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire
- 01 Apr 2015 No recent reports of development identified - Phase-III for Influenza virus infections (Prevention) in USA (IM)